Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $6.0 million.

  • Eton Pharmaceuticals' Gains from Investment Securities fell 194.18% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 194.18%. This contributed to the annual value of $5.9 million for FY2024, which is 2230.5% up from last year.
  • Eton Pharmaceuticals' Gains from Investment Securities amounted to $6.0 million in Q3 2025, which was down 194.18% from $6.0 million recorded in Q2 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Gains from Investment Securities peaked at $6.3 million during Q2 2024, and registered a low of $2000.0 during Q1 2024.
  • In the last 5 years, Eton Pharmaceuticals' Gains from Investment Securities had a median value of $1.1 million in 2021 and averaged $2.6 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 9889.5% in 2024, then soared by 30205785.0% in 2025.
  • Quarter analysis of 5 years shows Eton Pharmaceuticals' Gains from Investment Securities stood at $181000.0 in 2021, then fell by 13.26% to $157000.0 in 2022, then crashed by 57.96% to $66000.0 in 2023, then soared by 2454.55% to $1.7 million in 2024, then surged by 253.8% to $6.0 million in 2025.
  • Its last three reported values are $6.0 million in Q3 2025, $6.0 million for Q2 2025, and $6.0 million during Q1 2025.